Interview: Ferring Forges Ahead With mAbs For Reproductive Meds

15 Feb 2018

Antibody-based therapies have not really been investigated in the area of reproductive medicine and women’s health but Ferring is investing heavily to explore their potential, head of global pharmaceutical R&D Armin Metzger tells Scrip.

Brick wall — Ferring hopes to shed light on mAb research in reproductive medicine • Source: Shutterstock

Having announced plans to build a biotech center on home soil, Switzerland's Ferring Pharmaceuticals AS is exploring the use of monoclonal antibodies (mAbs) as treatments in its core areas of reproductive medicine and women’s health.

In an interview with Scrip, head of global pharmaceutical R&D Armin Metzger noted that traditionally Ferring had consolidated its position as a world leader of products based upon peptide hormones,...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

ASCO: DESTINY-Breast09 Strong, But May Need Mature OS Data To Change Practice

02 Jun 2025

• By Alaric DeArment

Data from AstraZeneca/Daiichi’s breast cancer trial showed positive PFS, but some oncologists are waiting for confirmation of statistically significant OS benefit.